1346936-27-3

Upstream product

• 1346936-32-0 N,N-bis(2-hydroxyethyl)-N-methyl-N-[4-(6-methyl-1,3,6,2-dioxazaborocan-2-yl)phenyl]methanaminium bromide 
• 51-75-2 nitrogen mustard 
• 138500-85-3 4-bromomethylphenylboronic acid pinacol ester 
• 55-86-7 mechlorethamine hydrochloride 

Downstream Products

• 1346936-38-6 [CH₃N(C₂H₄Cl)2CH₂C₆H₄OBO₂C₂(CH₃)4]⁽¹⁺⁾*Br^(1-)=[CH₃N(C₂H₄Cl)2CH₂C₆H₄OBO₂C₂(CH₃)4]Br 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 51-75-2 nitrogen mustard 

Relevant academic research and scientific papers

ANTI-CANCER AGENTS

Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.

Hydrogen peroxide inducible DNA cross-linking agents: Targeted anticancer prodrugs

The major concern for anticancer chemotherapeutic agents is the host toxicity. The development of anticancer prodrugs targeting the unique biochemical alterations in cancer cells is an attractive approach to achieve therapeutic activity and selectivity. We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high level of reactive oxygen species (ROS) found in cancer cells to release the active chemotherapy agent. The activation mechanism was determined by NMR analysis. The activity and selectivity of these prodrugs toward ROS was determined by measuring DNA interstrand cross-links and/or DNA alkylations. These compounds showed 60-90% inhibition toward various cancer cells, while normal lymphocytes were not affected. To the best of our knowledge, this is the first example of H 2O2-activated anticancer prodrugs.